All In MedTech

FDA Clearance Tracker · P130022-S058

Senza Spinal Cord Stimulation (SCS) System and HFX iQ System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 24, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 24, 2024

Approved

Time to decision

180 days

Received Mar 28, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P130022-S058
Device name
Senza Spinal Cord Stimulation (SCS) System and HFX iQ System
Applicant location
Redwood City, CA
Received
Mar 28, 2024
Decided
Sep 24, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P130022

Device type

Device class
Class III

Every decision under product code LGW

FDA's approval statement

As written in FDA's record.

Approval for an update to the Clinical Summary manual to add 24-month results from their Senza-PDN study to demonstrate long-term safety and effectiveness of 10 kHz SCS therapy in treating painful diabetic neuropathy (PDN) patients.

Source documents

Other decisions for Nevro Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.